￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Medical News

FDA approves Takeda’s Alunbrig (brigatinib) as a new first-line treatment option for ALK
FDA approves Takeda’s Alunbrig (brigatinib) as a new first-line treatment option for ALK

2025-10-19 11:44:20

CAMBRIDGE, Mass. and OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceuticals, Inc. today announced that the U.S.

Check Details
FDA approves Takeda's Alunbrig (brigatinib) for the treatment of crizotinib-resistant ALK-positive metastatic non-small cell lung cancer_Canghule

2025-10-19 11:44:20

Check Details
Category
相关知识